Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
17.86
-0.43 (-2.32%)
At close: Jul 24, 2026, 4:00 PM EDT
17.75
-0.11 (-0.59%)
After-hours: Jul 24, 2026, 7:22 PM EDT

Quince Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-57.8-58.07-57.29-34.62-52.02-90.32
Net Income
-33.04-83.98-56.83-31.39-51.66-89.95
Earnings Per Share
-212.40-336.00-262.00-168.00-308.00-606.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
18.1617.7540.7875.0690.18106.8
Total Debt
0.2918.3614.7213.7500.42
Net Cash (Debt)
17.87-0.626.0761.3190.18106.38
Net Cash Growth
12.04%--57.48%-32.02%-15.23%-20.38%
Net Cash Per Share
57.59-2.41120.52329.29538.45715.93

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-39.45-41.43-31.9-18.29-44.04-62.93
Capital Expenditures
-0.35-0.35-0.26-0.16-0.13-0.18
Free Cash Flow
-39.8-41.78-32.16-18.45-44.17-63.11
Free Cash Flow Growth
------